Automatic Website Traffic RSS

AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

The latest trading session saw AbbVie (ABBV) ending at $164.25, denoting a +1.05% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.58%. On the ... read more

AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition

AbbVie (ABBV) stock gains as the company's JAK inhibitor, upadacitinib, succeeds in a Phase 3 trial for giant cell arteritis, an inflammatory condition. Read more here. read more

AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug

AbbVie's (ABBV) buyout target, Cerevel Therapeutics (CERE), announced positive data for its Parkinson's disease candidate tavapadon in a Phase 3 trial, Read more here. read more

AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis

Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with ... read more

Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally

It might have been a disaster, but biotech stock AbbVie (NASDAQ:ABBV) is turning things around. Reports of counterfeit Botox have emerged, and ... read more

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,095.97 today based on a price of $163.80 for ABBV at the time of writing. read more

Is Johnson & Johnson Stock A Better Pick Over AbbVie?

Firstly, looking at stock returns, ABBV stock has seen strong gains of 60% from levels of $105 in early January 2021 to around $170 now, versus a little change for JNJ, moving slightly from levels of ... read more

AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share

Pharmaceutical company AbbVie’s (NYSE:ABBV) arthritis drug, Humira, continues to dominate the market despite facing competition from heavily ... read more

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. read more

AbbVie's Options Frenzy: What You Need to Know

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. read more